EFPIA - NEWSLETTER

EFPIA Newsletter 02 November 2017

News

27 October 2017 27102017 EFPIA Welcomes Paediatric Medicines Regulation Report and Reiterates its Commitment...

Entitled: “10 years of the EU Paediatric Regulation,” the report furthermore recognises correctly the continuous commitment...

02 November 2017 02112017 EFPIA Statement on the Extension of Activities Concerning EU/US Site Inspections

The extension of operations is aimed at recognising inspections of manufacturing sites for human medicines conducted...

Blogs

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicine is a long, complex and risky process with no guarantees of success. Over the coming weeks, we look at a number of new medicines and the role that pharmaceutical incentives (or IP) have played in their development.

02 November 2017 02112017 Using Incentives as an Innovation Spring-Board to Treat MS

How incentives helped promote the development of Gilenya

02 November 2017 2112017 Incentives, IP and smaller companies; case story: TiGenix

IP rights and EU pharmaceutical incentives enable innovation for the cures of tomorrow

Events

21 NOV 2017

19 July 2017 War on Cancer – a patient’s journey The HAC, London, UK

3rd annual conference organised by The Economist Events

Learn more →

27 NOV 2017

14 July 2017 1st European Alliance for Personalised Medicine Congress Belfast, Northern Ireland

Personalising Your Health: A Global Imperative!

Learn more →

We published

Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing... 27 October 2017 (Publications)

A study by QuintilesIMS

Working together with patient groups 11 October 2017 (Publications)

A publication from the Patient Think Tank to provide guidance for collaboration

Health Collaboration Guide 2017 26 October 2017 (Publications)

Showcasing best practice collaborations between patient organisations and industry, but also local authorities, governments,...

What we are reading

Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer? 18 October 2017 (Labiotech)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶